GHRS
GH Research PLC
$13.08
0.09
(0.69%)
| Exchange: | NASDAQ |
| Market Cap: | 811.328M |
| Shares Outstanding: | 70M |
About The Company
| Sector: | Healthcare | |||||
| Industry: | Biotechnology | |||||
| CEO: | Velichka Valcheva | |||||
| Full Time Employees: | 50 | |||||
| Address: |
|
|||||
| Website: | https://www.ghres.com |
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate; and GH003, an intranasal 5-MeO-DMT product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.
Click to read more…
Revenue Segmentation
🔒 You are currently logged out
Income Statement
(* All numbers are in thousands)
🔒 You are currently logged out
Balance Sheet
(* All numbers are in thousands)
🔒 You are currently logged out
Cash Flow Statement
(* All numbers are in thousands)
🔒 You are currently logged out
Analyst Estimates
(* All numbers are in thousands)
🔒 You are currently logged out
Current Key Metrics
🔒 You are currently logged out
Forward P/E Ratios
🔒 You are currently logged out
SWOT Analysis
🔒 You are currently logged out
At what price to buy it? –
Intrinsic Value Calculator
🔒 Premium Feature
Log in to access the GHRS Intrinsic Value Calculator
Get comprehensive stock analysis with premium features
🔒 You are currently logged out
MS_Stock_Embed class not found. Please check plugin configuration.
